Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 5/2012

01.10.2012 | Review

Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?

verfasst von: Richard A Steinman, Adam M Brufsky, Steffi Oesterreich

Erschienen in: Breast Cancer Research | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Zoledronic acid (ZA) is an imidazole-containing bisphosphonate that has been extensively studied as an osteoclast inhibitor. ZA decreases bone turnover and has been effective in limiting osteolysis in metastatic cancers, including breast cancer. Recent clinical trials that demonstrated enhancement of disease-free survival by bisphosphonates have prompted interest in bisphosphonates as anti-cancer agents. ZA, for example, increased disease-free survival in postmenopausal and in premenopausal, hormone-suppressed breast cancer patients. Intriguingly, however, there was a lack of an anti-cancer effect of ZA in premenopausal women without ovarian suppression. These observations have prompted the conjecture that anti-cancer effects of ZA are limited to estrogen-poor environments. This review explores possible mechanisms compatible with differences in ZA activity in premenopausal women compared with postmenopausal (or hormone-suppressed) women.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE: Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res. 2007, 13 (18 Pt 1): 5406-5410.CrossRefPubMed
2.
Holen I, Coleman RE: Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010, 12: 214-10.1186/bcr2769.CrossRefPubMedPubMedCentral
3.
Aapro M, Saad F, Costa L: Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist. 2010, 15: 1147-1158. 10.1634/theoncologist.2007-0245.CrossRefPubMedPubMedCentral
4.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011, 12: 631-641. 10.1016/S1470-2045(11)70122-X.CrossRefPubMed
5.
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011, 365: 1396-1405. 10.1056/NEJMoa1105195.CrossRefPubMed
6.
Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010, 21: 2188-2194. 10.1093/annonc/mdq217.CrossRefPubMed
7.
Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA: Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012, 118: 1192-1201. 10.1002/cncr.26313.CrossRefPubMed
8.
Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL: Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009, 117: 603-609. 10.1007/s10549-009-0332-2.CrossRefPubMedPubMedCentral
9.
Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P: Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012, 12: 40-48. 10.1016/j.clbc.2011.08.002.CrossRefPubMed
10.
Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K: The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 2009, 44: 908-916. 10.1016/j.bone.2009.01.010.CrossRefPubMedPubMedCentral
11.
Lipton A, Cook RJ, Major P, Smith MR, Coleman RE: Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007, 12: 1035-1043. 10.1634/theoncologist.12-9-1035.CrossRefPubMed
12.
van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996, 98: 698-705. 10.1172/JCI118841.CrossRefPubMedPubMedCentral
13.
Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002, 291: 680-686. 10.1006/bbrc.2002.6510.CrossRefPubMed
14.
Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY: Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res. 2008, 14: 3306-3311. 10.1158/1078-0432.CCR-07-4749.CrossRefPubMed
15.
Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010, 11: 421-428. 10.1016/S1470-2045(10)70054-1.CrossRefPubMedPubMedCentral
16.
Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, Heinrigs M, Rammel G, Zwingers T, Sommer H, Friese K, Janni W: Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010, 30: 1807-1813.PubMed
17.
Yokota A, Kimura S, Tanaka R, Takeuchi M, Yao H, Sakai K, Nagao R, Kuroda J, Kamitsuji Y, Kawata E, Ashihara E, Maekawa T: Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk Res. 2010, 34: 793-799. 10.1016/j.leukres.2009.08.034.CrossRefPubMed
18.
Sethi N, Dai X, Winter CG, Kang Y: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011, 19: 192-205. 10.1016/j.ccr.2010.12.022.CrossRefPubMedPubMedCentral
19.
Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003, 425: 841-846. 10.1038/nature02040.CrossRefPubMed
20.
Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S: Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007, 130: 811-823. 10.1016/j.cell.2007.07.025.CrossRefPubMed
21.
Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005, 23: 4925-4935. 10.1200/JCO.2005.06.091.CrossRefPubMed
22.
Liu CC, Howard GA: Bone-cell changes in estrogen-induced bone-mass increase in mice: dissociation of osteoclasts from bone surfaces. Anat Rec. 1991, 229: 240-250. 10.1002/ar.1092290211.CrossRefPubMed
23.
Li L, Neaves WB: Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006, 66: 4553-4557. 10.1158/0008-5472.CAN-05-3986.CrossRefPubMed
24.
McLean RR: Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009, 7: 134-139. 10.1007/s11914-009-0023-2.CrossRefPubMed
25.
Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, Poutahidis T, Taylor CL, Jackson EA, Hewes C, Lyle S, Cerny A, Bowen G, Cerny J, Moore N, Kurt-Jones EA, Erdman SE: Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev. 2010, 19: 1153-1166. 10.1089/scd.2009.0439.CrossRefPubMedPubMedCentral
26.
27.
Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D: Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, activin and inhibin. Mol Cell Endocrinol. 2009, 310: 11-20. 10.1016/j.mce.2009.07.001.CrossRefPubMedPubMedCentral
28.
Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K, Gerber B: Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis. Oncol Rep. 2005, 13: 81-88.PubMed
29.
Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003, 9: 2893-2897.PubMed
30.
Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Monkkonen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M: Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010, 14: 2803-2815. 10.1111/j.1582-4934.2009.00926.x.CrossRefPubMed
31.
Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C, Perrot-Applanat M: Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol. 2000, 279: H2033-H2042.PubMed
32.
Dadiani M, Seger D, Kreizman T, Badikhi D, Margalit R, Eilam R, Degani H: Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc. Endocr Relat Cancer. 2009, 16: 819-834. 10.1677/ERC-08-0249.CrossRefPubMed
33.
Saarinen NM, Abrahamsson A, Dabrosin C: Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer. 2010, 127: 737-745. 10.1002/ijc.25052.CrossRefPubMed
34.
Sisci D, Middea E, Morelli C, Lanzino M, Aquila S, Rizza P, Catalano S, Casaburi I, Maggiolini M, Ando S: 17β-estradiol enhances alpha(5) integrin subunit gene expression through ERα-Sp1 interaction and reduces cell motility and invasion of ERα-positive breast cancer cells. Breast Cancer Res Treat. 2010, 124: 63-77. 10.1007/s10549-009-0713-6.CrossRefPubMed
35.
Bellahcene A, Chaplet M, Bonjean K, Castronovo V: Zoledronate inhibits αvβ3 and αvβ5 integrin cell surface expression in endothelial cells. Endothelium. 2007, 14: 123-130. 10.1080/10623320701347187.CrossRefPubMed
36.
Tsagozis P, Eriksson F, Pisa P: Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother. 2008, 57: 1451-1459. 10.1007/s00262-008-0482-9.CrossRefPubMed
37.
38.
Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA: 17β-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood. 2004, 104: 1404-1410. 10.1182/blood-2003-10-3380.CrossRefPubMed
39.
Hsieh YC, Frink M, Hsieh CH, Choudhry MA, Schwacha MG, Bland KI, Chaudry IH: Downregulation of migration inhibitory factor is critical for estrogen-mediated attenuation of lung tissue damage following trauma-hemorrhage. Am J Physiol Lung Cell Mol Physiol. 2007, 292: L1227-L1232. 10.1152/ajplung.00479.2006.CrossRefPubMed
40.
Routley CE, Ashcroft GS: Effect of estrogen and progesterone on macrophage activation during wound healing. Wound Repair Regen. 2009, 17: 42-50. 10.1111/j.1524-475X.2008.00440.x.CrossRefPubMed
41.
Menzies FM, Henriquez FL, Alexander J, Roberts CW: Selective inhibition and augmentation of alternative macrophage activation by progesterone. Immunology. 2011, 134: 281-291. 10.1111/j.1365-2567.2011.03488.x.CrossRefPubMedPubMedCentral
42.
Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, Touraine JL, Clezardin P: High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vγ9Vδ2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011, 71: 4562-4572. 10.1158/0008-5472.CAN-10-3862.CrossRefPubMed
43.
Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A: Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003, 102: 2310-2311. 10.1182/blood-2003-05-1655.CrossRefPubMed
44.
Nussbaumer O, Gruenbacher G, Gander H, Thurnher M: DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes. Blood. 2011, 118: 2743-2751. 10.1182/blood-2011-01-328526.CrossRefPubMed
45.
Friedl A, Jordan VC: Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. Eur J Cancer. 1994, 30A: 1559-1564.CrossRefPubMed
46.
Jiang X, Ellison SJ, Alarid ET, Shapiro DJ: Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene. 2007, 26: 4106-4114. 10.1038/sj.onc.1210197.CrossRefPubMed
47.
Dosiou C, Hamilton AE, Pang Y, Overgaard MT, Tulac S, Dong J, Thomas P, Giudice LC: Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J Endocrinol. 2008, 196: 67-77. 10.1677/JOE-07-0317.CrossRefPubMed
48.
Check JH, Sansoucie L, Chern J, Dix E: Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 2010, 30: 119-122.PubMed
49.
Gallo M, De Luca A, Lamura L, Normanno N: Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol. 2012, 23: 597-604. 10.1093/annonc/mdr159.CrossRefPubMed
50.
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007, 449: 557-563. 10.1038/nature06188.CrossRefPubMed
51.
Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T: Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004, 10: 4559-4567. 10.1158/1078-0432.CCR-03-0325.CrossRefPubMed
52.
Hasmim M, Bieler G, Ruegg C: Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost. 2007, 5: 166-173. 10.1111/j.1538-7836.2006.02259.x.CrossRefPubMed
53.
Wu Q, Chambliss K, Umetani M, Mineo C, Shaul PW: Non-nuclear estrogen receptor signaling in the endothelium. J Biol Chem. 2011, 286: 14737-14743. 10.1074/jbc.R110.191791.CrossRefPubMedPubMedCentral
54.
Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME: Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 2010, 121: 293-300. 10.1007/s10549-009-0458-2.CrossRefPubMed
55.
Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T: Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One. 2008, 3: e2238-10.1371/journal.pone.0002238.CrossRefPubMedPubMedCentral
56.
Fromigue O, Kheddoumi N, Body JJ: Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer. 2003, 89: 178-184. 10.1038/sj.bjc.6601009.CrossRefPubMedPubMedCentral
57.
Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A, Ditonno P, Musto P, D'Auria F, Ricciardi MR, Dammacco F, Ribatti D, Vacca A: Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer. 2010, 46: 420-429. 10.1016/j.ejca.2009.10.019.CrossRefPubMed
58.
Khan KN, Masuzaki H, Fujishita A, Kitajima M, Sekine I, Matsuyama T, Ishimaru T: Estrogen and progesterone receptor expression in macrophages and regulation of hepatocyte growth factor by ovarian steroids in women with endometriosis. Hum Reprod. 2005, 20: 2004-2013. 10.1093/humrep/deh897.CrossRefPubMed
59.
Zhang HZ, Bennett JM, Smith KT, Sunil N, Haslam SZ: Estrogen mediates mammary epithelial cell proliferation in serum-free culture indirectly via mammary stroma-derived hepatocyte growth factor. Endocrinology. 2002, 143: 3427-3434. 10.1210/en.2002-220007.CrossRefPubMed
60.
Rodrigues GA, Park M, Schlessinger J: Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 1997, 16: 2634-2645. 10.1093/emboj/16.10.2634.CrossRefPubMedPubMedCentral
61.
Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C: Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 2007, 67: 2062-2071. 10.1158/0008-5472.CAN-06-3895.CrossRefPubMed
62.
Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, Ponten F, Weinberg RA, McAllister SS: Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest. 2011, 121: 784-799. 10.1172/JCI43757.CrossRefPubMedPubMedCentral
63.
Lu R, Serrero G: Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proc Natl Acad Sci USA. 2001, 98: 142-147. 10.1073/pnas.98.1.142.CrossRefPubMed
64.
Kars MD, Iseri OD, Ural AU, Gunduz U: In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res. 2007, 27: 4031-4037.PubMed
65.
Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Redini F, Rogers M, Heymann D: Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med. 2008, 12: 928-941. 10.1111/j.1582-4934.2008.00141.x.CrossRefPubMedPubMedCentral
66.
Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Satomi K: Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res. 2010, 30: 3565-3571.PubMed
67.
Porter W, Saville B, Hoivik D, Safe S: Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol. 1997, 11: 1569-1580. 10.1210/me.11.11.1569.CrossRefPubMed
68.
Cooper LF, Tiffee JC, Griffin JP, Hamano H, Guo Z: Estrogen-induced resistance to osteoblast apoptosis is associated with increased hsp27 expression. J Cell Physiol. 2000, 185: 401-407. 10.1002/1097-4652(200012)185:3<401::AID-JCP10>3.0.CO;2-C.CrossRefPubMed
69.
Dalenc F, Giamarchi C, Petit M, Poirot M, Favre G, Faye JC: Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res. 2005, 7: R1159-R1167. 10.1186/bcr1357.CrossRefPubMedPubMedCentral
70.
Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009, 15: 68-74. 10.1038/nm.1908.CrossRefPubMed
71.
72.
Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010, 102: 1099-1105. 10.1038/sj.bjc.6605604.CrossRefPubMedPubMedCentral
Metadaten
Titel
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
verfasst von
Richard A Steinman
Adam M Brufsky
Steffi Oesterreich
Publikationsdatum
01.10.2012
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2012
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3223

Weitere Artikel der Ausgabe 5/2012

Breast Cancer Research 5/2012 Zur Ausgabe

Viewpoint

Slugging their way to immortality: driving mammary epithelial cells into a stem cell-like state

Viewpoint

New insights into signalling networks regulating breast cancer stem cells

Research article

p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells

Viewpoint

Who's driving anyway? Herculean efforts to identify the drivers of breast cancer

Research article

A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion

Research article

Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise